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abstract
PURPOSE Salvage autologous stem-cell transplantation (sASCT) in patients with multiple myeloma (MM) re-
lapsing after a prior autologous stem-cell transplantation leads to increased remission duration and overall
survival. We report a comprehensive study on patient-reported outcomes, including quality of life (QoL) and pain
in sASCT.
METHODS Patients were randomly assigned to either sASCT or nontransplantation consolidation (NTC). Pain and
QoL were assessed as secondary outcomes using validated QoL instruments (European Organisation for
Research and Treatment of Cancer QLQ-C30 and myeloma-speciﬁc module, QLQ-MY20; the Brief Pain In-
ventory [Short Form]; and the Leeds Assessment of Neuropathic Symptoms and Signs [Self-Assessment] scale).
RESULTS A total of 288 patients (. 96%) consented to the QoL substudy. The median follow-up was 52 months.
The European Organisation for Research and Treatment of Cancer QLQ-C30 Global health status scores were
higher (better) in the NTC group at 100 days after random assignment (P = .0496), but not at later time points.
Pain interference was higher (worse) in the sASCT group than in the NTC group at 6 months after random
assignment (P = .0267), with patients with sASCT reporting higher scores for Pain interference with daily living
for up to 2 years after random assignment. Patients reporting lower concerns about adverse effects of treatment
after sASCT had a time to progression advantage.
CONCLUSION Patients with sASCT with relapsed MM demonstrated a comparative reduction in QoL and greater
impact of treatment adverse effects lasting for 6 months and up to 2 years for pain, after which patients who had
received sASCT reported better outcomes. Patients who experienced lower adverse effects after sASCT had
longer time to progression and overall survival, showing the need to improve symptom management peri-
transplantation. To our knowledge, this study provides the most comprehensive picture of QoL before and after
sASCT in patients with relapsed MM.
J Clin Oncol 37:1617-1628. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Despite advances in novel antimyeloma agents,1-4 the
use of a salvage autologous stem-cell transplantation
(sASCT) has continued to represent an option in well-
selected patients with multiple myeloma (MM) because
of the potential for sustained disease control. sASCT
was originally supported by retrospective, registry-
based, or single-center analyses,5-8 but deﬁnitive evi-
dence of its efﬁcacy in terms of signiﬁcantly improved
time to progression (TTP), progression-free survival
(PFS), and overall survival (OS) was provided by the UK
National Cancer Research Institute Myeloma X trial.9,10
With improving survival, MM is being experienced by
an increasing proportion of patients as a chronic
illness.11,12 However, even myeloma in remission may
be associated with many symptoms, which often arise
as a consequence of myeloma itself, its treatment, and
interactions with comorbid conditions accompanying
aging. A cumulative burden of symptoms and treat-
ment adverse effects, including various forms of pain,
all affect health-related quality of life (QoL).13,14 There
has been growing interest in the methodology of evalu-
ating patient-reported outcomes (PROs) to measure the
impact of both novel agents and autologous stem-cell
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transplantation (ASCT) onQoL in patients withMM.15-18 Studies
have also reported on PROs in larger cohorts of patients un-
dergoing ASCT and allogeneic transplantations for other con-
ditions and in older populations.19-23 However, few studies have
examined the years after transplantation that patients with MM
can now expect to survive.
A secondary aim of Myeloma X was to evaluate the impact
of sASCT compared with nontransplantation consolidation
(NTC) with oral cyclophosphamide once per week on PROs
relating to QoL and pain at ﬁrst relapse after a prior ASCT
and after reinduction chemotherapy. The hypothesis was
that ASCT was expected to be superior to NTC in terms of
TTP. Therefore, ASCT-related toxicity in the short term and
its potential impact on QoL, as well as patients’ long-term
QoL, were of interest. Furthermore, we sought to evaluate
the association of QoL at random assignment with sub-
sequent clinical outcomes and to identify patient subgroups
that may gain most QoL beneﬁt from sASCT.
METHODS
Study Design
Patients with symptomatic, measurable MM were eligible if
they required treatment of ﬁrst progressive disease (as
deﬁned by the International Myeloma Working Group cri-
teria24 at least 18 months after a prior ASCT). Inclusion and
exclusion criteria and the trial procedures have been de-
scribed in detail previously9,10 and are summarized in the
trial CONSORT diagram (Fig 1) and Data Supplement.
End Points
The primary end point was TTP; secondary end points were
response rate, PFS, OS, toxicity and safety, pain, and QoL.
Patient-Reported Outcomes
Pain and QoL were assessed in patients consenting to the
QoL substudy. These patients were willing and able to
complete the pain and QoL questionnaires at speciﬁed time
points throughout the study. All instruments were self-
administered to avoid interviewer bias and to enable the
patients to complete the questionnaires at home if they
preferred.
The European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
and the EORTC myeloma-speciﬁc module (EORTC QLQ-
MY20), were used to assess QoL during reinduction and
randomized treatment (Data Supplement). Pain experience
was captured using the Brief Pain Inventory (Short Form)
[BPI-SF], which assesses the severity of pain and its impact
on aspects of daily living in patients with chronic pain.25 The
Leeds Assessment of Neuropathic Symptoms and Signs
(Self-Assessment; S-LANSS) pain scale was administered
as a diagnostic tool to assess the extent to which the pain
was neuropathic.26
Questionnaires were administered before registration and
after completion of reinduction. For randomly assigned
patients, the questionnaires were administered before
randomization, unless within 2 weeks of the previous
questionnaires. These questionnaires were administered in
the clinic. Questionnaires were then sent by mail at
100 days after random assignment, 6 and 12 months after
random assignment, and then annually until the last ran-
domly assigned patient was 2 years after random assign-
ment (Fig 1) in the absence of disease progression. In this
analysis, all data up to 2 years after random assignment are
included.
Statistical Analysis
Sample size and trial details have been described
previously.9,10 The cutoff date for this analysis was July 14,
2015. The intention-to-treat population for the QoL sub-
study included all consenting patients who had completed
at least one questionnaire. All statistical analyses were
undertaken in SAS (version 9.4; SAS Institute, Cary, NC). All
statistical tests were two-sided and were considered sig-
niﬁcant at the 5% level.
sASCT was expected to be superior to NTC in terms of TTP.
Therefore, ASCT-related toxicity in the short term and its
potential impact on QoL, as well as patients’ long-term QoL,
were of interest. EORTC QLQ-C30, EORTC QLQ-MY20, the
S-LANSS pain scale, and the BPI-SF were used to measure
temporal changes in patient-assessed QoL and pain, and
their association with treatment. Of individual interest were
the QLQ-C30 Global health status score, BPI-SF Pain in-
terference scale, and MY20 Side effects of treatment
subscale. Adjustments to the 5% signiﬁcance level were
not made for repeating the analysis for these scales be-
cause they were deﬁned prospectively as being of indi-
vidual interest in the study Statistical Analysis Plan, which
was ﬁnalized before any analysis was undertaken. No
power calculations were prespeciﬁed for these pro-
spectively deﬁned scales. For all other QLQ-C30, QLQ-
MY20, BPI-SF subscales, and the S-LANSS, no statistical
hypothesis testing was performed to compare between
treatment groups.
QoL subscales were summarized using means, 95% CIs,
and differences between the two groups. For randomly
assigned patients, multilevel repeated mixed model ana-
lyses, which allowed for randomized treatment, time ef-
fects, treatment-time interactions, and baseline QoL (ﬁxed
effects), and patient and patient-time interaction (random
effects) were used. Additional details are given in the Data
Supplement.
RESULTS
Patients and Treatment
Between April 16, 2008, and November 19, 2012, 288 of
the 297 patients registered consented to the QoL substudy;
174 patients were subsequently randomly assigned to
receive sASCT (n = 89; 88 consented to the QoL substudy)
or NTC (n = 85; 83 consented). Baseline demographic and
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Eligible patients registered 
(N = 297)
Received reinduction treatment 
(n = 293)
Did not have PBSC mobilization and 
harvest (n = 166)
Had adequate stem cells stored 
(n = 123)
Had adequate stem cells after mobilization 
(n = 70)
Withdrew prior to mobilization
(n = 3)
Had ≥ stable disease response to reinduction 
(n = 279)
Randomly assigned to high-dose
melphalan and ASCT 
(n = 89)
Received no consolidation treatment 
(n = 6)
Randomly assigned to cyclophosphamide
once per week 
(n = 85)
Received no consolidation treatment  
(n = 1)
Eligible and willing patients
randomly assigned 
(n = 174)
Consented to QoL substudy (n = 288)
Completed baseline questionnaires (n = 247)
Missing questionnaires (n = 41)
Completed end-of-reinduction 
   questionnaires
Missing questionnaires
  (n = 194)
  (n = 78)
Received no trial treatment
Withdrew and received no trial treatment
(n = 1)
(n = 3)
(n = 7)
(n = 1)
(n = 2)
(n = 2)
(n = 2)
Withdrew during reinduction treatment
Had no central laboratory response
   assessment
Had progressive disease
Died (without progressive disease)
   before response assessment
Completed only one cycle of
   reinduction therapy
Withdrew during PBSC mobilization
Died during PBSC mobilization 
                  (n = 7; with progressive disease, n = 6)
Had progressive disease
Did not mobilize sufficient stem cells
(n = 2)
(n = 1)
(n = 30)
Withdrew and did not undergo
   PBSC mobilization
Died without undergoing PBSC
Had progressive disease
Did not undergo PBSC mobilization
   because of clinician decision
(n = 3)
(n = 17)
(n = 1)
(n = 22)
Withdrew before randomization screening      (n = 3)
Withdrew before randomization screening
   and was subsequently found to have
   progressed on the same day
Withdrawn by clinician                                     (n = 12)
Died before     (n = 3; n = 2 with progressive disease)
randomization screening
Consented to QoL substudy and were
   randomly assigned
In high-dose melphalan and ASCT group
In cyclophosphamide once-per-week group
Completed prerandomization questionnaires
High-dose melphalan and ASCT group
In cyclophosphamide once-per-week group
Missing questionnaires
(n = 171)
    (n = 1)
(n = 88)
(n = 83)
(n = 102)
(n = 53)
(n = 49)
(n = 69)
TTP
Had progressive disease (n = 71)
Were progression free (n = 18)
Completed 100-day questionnaires   (n = 131)
   High-dose melphalan and ASCT group (n = 66)
   Cyclophosphamide once-per-week group   (n = 65)
Missing questionnaires (n = 23)
Progressed or died before 100 days   (n = 17)
   High-dose melphalan and ASCT group  (n = 6)
   Cyclophosphamide once-per-week group (n = 11)
Progressed or died before 6 months   (n = 12)
   High-dose melphalan and ASCT group  (n = 3)
   Cyclophosphamide once-per-week group (n = 9)
Progressed or died before 12 months   (n = 39)
   High-dose melphalan and ASCT group  (n = 16)
   Cyclophosphamide once-per-week group (n = 23)
Progressed or died before 2 years   (n = 48)
   High-dose melphalan and ASCT group (n = 24)
   Cyclophosphamide once-per-week group  (n = 24)
Progressed or died before 3 years   (n = 20)
   High-dose melphalan and ASCT group (n = 14)
   Cyclophosphamide once-per-week group  (n = 6)
Progressed or died before 4 years   (n = 8)
   High-dose melphalan and ASCT group (n = 7)
   Cyclophosphamide once-per-week group  (n = 1)
Completed 6-month questionnaires (n = 125)
   High-dose melphalan and ASCT group  (n = 71)
   Cyclophosphamide once-per-week group  (n = 54)
Missing questionnaires (n = 17)
Completed 12-month questionnaires  (n = 95)
   High-dose melphalan and ASCT group  (n = 60)
   Cyclophosphamide once-per-week group (n = 35)
Missing questionnaires (n = 8)
Completed 2-year questionnaires  (n = 46)
   High-dose melphalan and ASCT group  (n = 36)
   Cyclophosphamide once-per-week group (n = 10)
Missing questionnaires (n = 9)
Completed 3-year questionnaires  (n = 19)
   High-dose melphalan and ASCT group  (n = 15)
   Cyclophosphamide once-per-week group (n = 4)
Missing questionnaires (n = 16)
Completed 4-year questionnaires  (n = 8)
   High-dose melphalan and ASCT group  (n = 6)
   Cyclophosphamide once-per-week group (n = 2)
Missing questionnaires (n = 19)
OS
Had died (n = 31)
Are alive (n = 58)
TTP
Had progressive disease (n = 75)
Are progression free (n = 10)
OS
Had died (n = 44)
Are alive  (n = 41)
Had PBSC mobilization and harvest
(Had sufficient stem cells stored
   from previous harvest
                 (n = 110)
                  [n = 26])
FIG 1. CONSORT diagram for
Myeloma X study, including
details of European Organisa-
tion for Research and Treat-
ment of Cancer (EROTC) QLQ-
C30 and MY20 questionnaire
return. ASCT, autologous stem-
cell transplantation; OS, overall
survival; PBSC, peripheral-
blood stem cell; QoL, quality of
life; TTP, time to progression.
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disease characteristics were well balanced between the
treatment groups (Table 1), except for a higher proportion
of patients with International Staging System III in the
transplantation group. Patients consenting to the QoL
substudy were similar to those who did not consent at
registration and randomization (Data Supplement).
Questionnaire Compliance
Compliance was good, with 76.1% of all expected ques-
tionnaires returned among consenting patients and similar
rates of compliance comparing randomly assigned groups
(Data Supplement). The greatest rate of noncompliance for
EORTC QLQ-C30 and QLQ-MY20 questionnaires was at the
randomization baseline time point (59.6% complying; Data
Supplement). For the S-LANSS and BPI-SF questionnaires,
compliance was slightly less (54.4% and 53.8%, re-
spectively; Data Supplement).
Subsequently, among the randomly assigned QoL pop-
ulation, more patients in the sASCT group completed the
QLQ-C30, MY20, and other questionnaires at later time
points, owing to the increased TTP (median, 19 months;
95% CI, 16 to 26 months; v 11 months; 95% CI, 9 to 12
months]; hazard ratio [HR], 0.45; 95%CI, 0.31 to 0.64; log-
rank P , .001; Data Supplement).
QoL and Pain With Respect to Reinduction Treatment
The adjusted means and 95% CIs (Data Supplement) with
baseline mean scores (Table 1) show that the majority of
adjusted subscale means had changed compared with the
trial entry subscale means. Global health status, Fatigue,
and Diarrhea demonstrated medium-sized, clinically rele-
vant differences.27 Role functioning, Social functioning,
Nausea/vomiting, Appetite loss, Constipation, Insomnia,
and Dyspnea demonstrated small clinically relevant dif-
ferences.27 The BPI-SF Pain severity score was similar to
trial entry, but the Pain interference score increased slightly
(Data Supplement).
QoL and Pain With Respect to Randomized Treatment
Figures 2 and 3 and the Data Supplement show the ad-
justed mean subscale scores of the EORTC QLQ-C30 and
MY20 and the mean BPI-SF scores. It should be noted that
there were imbalances at randomization baseline in
a number of subscales, including Global health status
(Table 1). In the majority of patients, the QoL subscale
seemed to be worse in the sASCT group. The reasons for
this imbalance could not be identiﬁed.
Global health status subscale was signiﬁcantly different
between groups at 100 days after random assignment
(P = .0496; Table 2), but at no other time points after
random assignment (Table 2). The Global health status
score was higher at 100 days after random assignment by
9.2 points in the NTC group of the trial—a small-medium
size difference.27 This deterioration in Global health status
for patients receiving sASCT compared with NTC dissipated
to a trivial27 difference at 6 months and a smaller trivial
difference at 1 year. The difference at 2 years favored
sASCT but was still trivial. The Side effects of treatment
subscale was higher in the sASCT group of the trial at
100 days and 6 months after random assignment (Table 2;
Fig 2). This difference was small (7.6 and 5.9 points at
100 days and 6 months, respectively) and subsequently
dissipated.
There was no signiﬁcant difference between the trial groups
for Pain interference, adjusted for baseline score and
baseline neuropathic pain level at the 100-day post-
randomization time point (P = .0602; Table 2); there were
signiﬁcant differences at 6months (P = .0267; Table 2) and
similar signiﬁcant differences up to 2 years (Table 3; Data
Supplement). In all of the time points considered, Pain
interference was approximately 1 point lower in the NTC
group, a clinically relevant difference. Sensitivity analysis
under an assumption of data missing at random using
multiple imputation by chained equations provided similar
estimates, but in the case of Global health status, this was
not signiﬁcant (Data Supplement).
Subgroup Analysis
Post hoc exploratory analysis of key patient subgroups that
had previously been investigated for clinical outcomes (TTP
and OS) showed no signiﬁcant heterogeneity of treatment
effect on subscales of special interest: Global health status
(Data Supplement), Side effects of treatment (Data Sup-
plement), and BPI-SF Pain interference score (Data Sup-
plement). The greatest variability in estimates was observed
in the adverse cytogenetics risk group, which was small for
the intersection of patients with completed questionnaires
and available cytogenetics.
Association Between Baseline Scales and Outcome
Post hoc exploratory analysis of TTP by randomly assigned
allocation suggested that patients with Global health status
greater than median at randomization (Data Supplement)
and who received sASCT had a signiﬁcant TTP advantage
over those receiving NTC (HR, 0.3; 95% CI, 0.15 to 0.61;
P = .006). However, with multivariable Cox regression
analysis accounting for stratiﬁcation factors, this difference
was not signiﬁcant. Patients who reported a lower than
median score on the Side effects of treatment subscale
randomization and who received sASCT had a signiﬁcant
TTP advantage over those receiving NTC (HR, 0.24; 95%
CI, 0.10 to 0.55; P = .003). This survival difference was
maintained with multivariable Cox regression analysis (HR,
0.20; 95% CI, 0.04 to 1.00; P = .0499). Pain scores were
not found to be strongly predictive of outcome (TTP and OS;
Data Supplement).
DISCUSSION
Bony pain is a signiﬁcant feature of myeloma and persists
even when the disease is controlled because of both a lack
of bone repair and the mechanical stresses of movement.
This can persist into remission when the disease is no
1620 © 2019 by American Society of Clinical Oncology Volume 37, Issue 19
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TABLE 1. Patient Baseline Characteristics of the Quality of Life Substudy Population at Registration and Random Assignment
Characteristic Registration (n = 288) sASCT (n = 88) NTC (n = 83)
Age, years
Median 61 61 61
Range 38-75 40-73 40-73
Sex
Male 201 (69.8) 64 (72.7) 60 (72.3)
Female 87 (30.2) 24 (27.3) 23 (27.7)
Ethnicity
White 260 (90.3) 80 (90.9) 78 (94.1)
Asian 7 (2.3) 3 (3.3) 2 (2.4)
Black 13 (4.5) 3 (3.4) 2 (2.4)
Other 4 (1.4) 0 (0) 0 (0)
Not stated 5 (1.7) 2 (2.3) 1 (1.2)
International Staging System*
I 182 (63.2) 56 (63.6) 50 (60.2)
II 60 (20.8) 18 (20.5) 21 (25.3)
III 25 (8.7) 8 (9.1) 3 (3.6)
Missing 21 (7.3) 6 (6.8) 9 (10.8)
ECOG performance status
0 158 (54.9) 37 (42.0) 41 (49.4)
1 109 (37.8) 42 (47.7) 33 (39.8)
2 16 (5.6) 9 (10.2) 7 (8.4)
Missing 5 (1.7) 0 (0) 2 (2.4)
Isotype
IgG 186 (64.6) 60 (68.2) 56 (67.5)
IgA 53 (18.4) 13 (14.8) 17 (20.5)
Light chain only 26 (9.0) 6 (6.8) 7 (8.4)
IgM/IgD 3 (1.0) 1 (1.1) 1 (1.1)
Nonsecretory 9 (3.1) 3 (3.4) 2 (2.4)
Missing 11 (3.8)
TTP post-ASCT1, years
Median 2.5 2.6 2.5
Range 0.4-12.4 1.0-12.4 0.7-6.5
Missing 38 9 11
Cytogenetic features†
t(4;14) 13 (9.1) 5 (11.6) 3 (7.0)
t(11;14) 15 (10.5) 3 (7.0) 4 (9.3)
t(14;16) 3 (2.1) 0 (0) 2 (4.7)
Deletion 17p 10 (7.0) 4 (9.3) 1 (2.3)
Hyperdiploidy 19 (13.3) 4 (9.3) 5 (11.6)
Missing data/not tested 145 45 40
EORTC QLQ-C30 functional domain scores, mean (95% CI)
GHS/QoL 64.4 (61.5 to 67.3) 51.0 (44.7 to 57.3) 58.8 (52.5 to 65.2)
Physical functioning 71.4 (68.4 to 74.4) 63.1 (56.5 to 69.8) 71.2 (64.7 to 77.6)
(continued on following page)
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longer active and after systemic anticancer treatments have
ceased.11,28,29 This trial provides the most comprehensive
picture of PROs before, immediately after, and for a sub-
stantial time after sASCT.
Several studies have sought to describe the process of MM
treatment, including adverse effects of ASCT in terms of
PROs and overall QoL. Morbidity during ASCT is high, with
mucositis, emesis, and complications of bone marrow
depletion and sepsis. Many patients ﬁnd this period acutely
distressing and may display long-term psychological
changes. Sherman et al14 assessed a sample of 94 patients
undergoing ASCT using the Functional Assessment of
Cancer Therapy–Bone Marrow Transplant (FACT-BMT)
and symptom scales. They found that levels of physical and
functioning well-being were already low, and fatigue,
anxiety, and depression pain were prevalent at the pre-
transplantation assessment. After ASCT, there was a wors-
ening of transplantation-related concerns, depression, and
life satisfaction. Pain and physical functioning did not de-
teriorate. Older patients were no more compromised than
younger ones, conﬁrmed in another study of mixed hema-
tologic malignancies.15
Jim et al23 described the QoL effects of ASCT in MM in
a sample of 701 participants in the Blood and BoneMarrow
TABLE 1. Patient Baseline Characteristics of the Quality of Life Substudy Population at Registration and Random Assignment (continued)
Characteristic Registration (n = 288) sASCT (n = 88) NTC (n = 83)
Role functioning 63.6 (59.4 to 67.8) 46.5 (37.7 to 55.4) 60.2 (51.4 to 69.0)
Cognitive functioning 82.8 (80.2 to 85.5) 74.8 (68.1 to 81.6) 80.6 (74.1 to 87.1)
Emotional functioning 77.9 (75.2 to 80.6) 71.3 (65.7 to 77.0) 78.2 (71.1 to 85.4)
Social functioning 66.8 (62.8 to 70.8) 49.0 (40.3 to 57.7) 65.0 (56.8 to 73.2)
EORTC QLQ-C30 symptom domain scores, mean (95% CI)
Fatigue 36.7 (33.2 to 40.2) 54.5 (47.4 to 61.6) 41.5 (34.0 to 49.0)
Pain 37.7 (33.6 to 41.9) 43.4 (35.0 to 51.8) 35.4 (26.9 to 43.9)
Nausea/vomiting 5.2 (3.7 to 6.7) 9.9 (5.3 to 14.6) 9.2 (4.5 to 13.9)
Appetite loss 16.0 (12.9 to 19.2) 28.2 (19.7 to 36.7) 19.0 (10.5 to 27.6)
Constipation 13.4 (10.5 to 16.3) 22.6 (14.8 to 30.4) 17.0 (9.9 to 24.1)
Diarrhea 6.2 (4.2 to 8.1) 16.3 (8.3 to 24.4) 6.8 (2.9 to 10.7)
Insomnia 30.3 (26.0 to 34.5) 41.5 (32.0 to 51.0) 38.8 (28.7 to 48.8)
Dyspnea 22.2 (18.6 to 25.7) 28.3 (21.0 to 35.6) 15.6 (10.1 to 21.2)
Financial difﬁculties 22.1 (18.0 to 26.1) 27.5 (17.2 to 37.7) 19.7 (11.2 to 28.2)
EORTC QLQ-MY20 scores, mean (95% CI)
Disease symptoms 42.3 (39.0 to 45.7) 46.4 (38.8 to 54.0) 37.2 (28.8 to 45.6)
Adverse effects 29.1 (26.2 to 32.0) 24.0 (18.2 to 29.8) 21.0 (16.1 to 25.9)
Future perspective 13.0 (11.5 to 14.5) 25.2 (21.7 to 28.7) 25.1 (20.5 to 29.8)
Body image 20.2 (16.4 to 24.0) 34.6 (25.9 to 43.4) 27.9 (18.4 to 37.3)
BPI-SF, mean (95% CI)
Pain severity 2.9 (2.6 to 3.2) 3.5 (2.7 to 4.2) 3.1 (2.4 to 3.8)
Pain interference 2.7 (2.3 to 3.1) 4.0 (3.1 to 4.9) 3.5 (2.5 to 4.5)
S-LANSS
Neuropathic pain (S-LANSS $ 12)
Yes 15 (7.0) 14 (29.8) 10 (22.2)
No 155 (72.1) 28 (53.2) 26 (57.8)
Missing 45 (20.9) 8 (17.0) 9 (20.0)
NOTE. Data are No. (%) unless otherwise indicated.
Abbreviations: BPI-SF, Brief Pain Inventory (Short Form); ECOG, Eastern Cooperative Oncology Group; EORTC, European Organisation for
Research and Treatment of Cancer; GHS, Global health status; Ig, immunoglobulin; NTC, nontransplantation consolidation; QLQ-C30, core 30-
question quality of life questionnaire; QLQ-MY20, myeloma-speciﬁc 20-question quality of life questionnaire; QoL, quality of life; sASCT, salvage
autologous stem-cell transplantation; S-LANSS, Leeds Assessment of Neuropathic Symptoms and Signs (Self-Assessment); TTP, time to
progression.
*Higher stage indicates more severe disease.
†Percentage expressed as the proportion detected among those tested
1622 © 2019 by American Society of Clinical Oncology Volume 37, Issue 19
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Transplantation Clinical Trials Network 0902 trial. Using the
Medical Outcomes Study Short Form (a generic instrument
describing key dimensions of daily life), they were able to
describe four trajectories for physical and mental aspects of
QoL 100 days and 6 months after ASCT: low and stable;
average and declining, then stable; higher than average and
stable; and average and stable. They also concluded that
attrition in post-ASCT studies could give rise to overestimates
of QoL, but these are slight and consistent over time.
Novel agents in triplet combinations and their impact on
PROs have recently been reported in relapsed patients for
carﬁlzomib,30 ixazomib,31 and elotuzumab,32 where 43% to
62% of patients in these studies were treated for ﬁrst re-
lapse. Baseline and long-term on-treatment scores for the
scales of key interest were similar to those observed in this
study. Each novel agent improved PFS and showed no
detrimental long-term impact on Global health status.
These ﬁndings are important because others have shown
that baseline psychosocial factors and QoL after induction
and before ASCT, and the extent of treatment ad-
verse effects during ASCT, could be predictive of post-
transplantation adverse changes, including the ﬁnding of
post-traumatic stress disorder in some patients.33-35 Most
recently, O’Sullivan et al36 conﬁrmed that higher pre-
transplantation pain predicted lower physical well-being
and QoL. However, it should be noted that these studies
included a variety of hematologic malignancies, both au-
tograft and allograft, and a range of QoL measures.
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FIG 2. Baseline adjusted complete-case summary statistics (mean and 95% CI) scales from the European Organisation for Research and Treatment of
Cancer (EROTC) QLQ-C30 questionnaire in randomly assigned patients. Global health status/quality of life (QoL)-social functioning: higher score represents
better QoL/functioning; fatigue-body image loss: higher score represents worse symptoms/QoL. NTC, nontransplantation consolidation; sASCT, salvage
autologous stem-cell transplantation.
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Although the questionnaire compliance was good, a limi-
tation of this report is the low compliance at randomization
baseline for all questionnaires, which leads to a subsample
of data used in statistical models. In addition, there was an
imbalance in the QoL scores at randomization baseline,
with most scores better in the cyclophosphamide once-per-
week group. There was no reason identiﬁed for the reduced
compliance nor the baseline imbalance, with no signiﬁcant
differences identiﬁed in the time between trial registration,
randomization, and questionnaire completion, or an im-
balance in the same subsample of patients at trial regis-
tration or the end of reinduction. However, sensitivity
analysis found no evidence to reject an assumption of
missing at random, and multiple imputation provided
broadly similar results, with potentially a nonsigniﬁcant
difference in Global health status at 100 days post-ASCT.
We found that after entering the trial and after reinduction
with bortezomib, doxorubicin, and dexamethasone, there
were adverse changes in many aspects of QoL reﬂecting
the intensity of treatment; these were of medium clinical
signiﬁcance only for Global health status, Fatigue, and
Diarrhea. Importantly, psychological aspects were not
compromised, because these have been shown to predict
worse outcomes after hematopoietic stem-cell trans-
plantation (HSCT) elsewhere.33 In the early postrandomiza-
tion period, patients who had undergone sASCT showed
evidence of a small reduction in aspects of QoL. At 100 days,
only Role functioning and Global health status were signiﬁ-
cantly higher in the NTC arm, with a magnitude indicating
a small clinical difference. However, by 1 year after random
assignment, this difference in Global health status was not
observed.
There was evidence from the S-LANSS scale that the
neuropathic component of pain was increased at 100 days
after transplantation, but not later. Pain interference with
daily living using the BPI-SF also increased in patients with
sASCT and was seen until 2 years after random assign-
ment. Drugs used in the ASCT process are not usually
associated with direct neuropathic changes. However,
systemic inﬂammation can give rise to increased pain
sensitivity, probably because of the effect of proin-
ﬂammatory cytokines directly sensitizing peripheral pain
pathways.37 We have shown in another cohort study of
patients with MM in remission that pain level as measured
by BPI-SF was correlated with circulating interleukin-6.38 In
sASCT, the increased risk of systemic inﬂammation, in-
cluding sepsis, could condition patients with existing neural
damage to express more pain. Prolonged increased pain
after HSCT has not been reported previously, possibly
because others have not used a standardized painmeasure
such as BPI-SF, with its more sensitive, speciﬁc Pain
interference scale.
The MY-20 module has a speciﬁc scale for detecting
concerns about Side effects of treatment. Although this
score was increased in patients randomly assigned to
sASCT at 100 days and 6 months, the magnitude of this
change was small and disappeared subsequently. Patients
with sASCT who reported a lower (ie better) than median
level of concern about adverse effects had signiﬁcant TTP
and OS advantages, even after adjustment in a multivari-
able Cox regression analysis. One likely interpretation of this
in patients undergoing ASCT is that maximal efforts should
be made to minimize the emergence of adverse effects of
the procedure and to optimize their management. El-
Jawahri et al39 reported on the effect of a randomized
trial of in-patient palliative care on QoL of patients with
HSCT. This novel intervention led to a smaller increase in
depression, lower anxiety, and less increase in symptom
burden at 2 weeks post-HSCT and also a smaller reduction
in QoL at 2 weeks, with higher QoL at 3 months.
This study is subject to several limitations, including an
open-label design, in which lack of blinding could be rel-
evant where subjective end points such as pain, other
symptoms, treatment adverse effects, and QoL are of in-
terest. We relied on patient reports using paper-based
questionnaires. These are subject to problems related to
adherence, especially when patients are experiencing
periods of increased illness. We found the adherence and
missing data rates to be comparable to other studies in this
population, using the same or similar instruments. Attrition
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FIG 3. Baseline adjusted complete-case summary statistics (mean and 95% CI) scales from the European Organisation for Research and Treatment of
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rates are possibly a source of bias if they occur differ-
entially in allocated treatment arms. It has been shown
that attrition can overestimate QoL scores, but this effect
can be consistent over time and between allocated
treatment arms.23 This is perhaps relevant in this study,
where PROs were collected up until the time of disease
progression.
The small and diminishing differences in Global health
status and Side effects of treatment need to be considered
alongside the results of Myeloma X, which showed a sig-
niﬁcant beneﬁt of sASCT on OS. The beneﬁts of sASCT
should be considered alongside the relatively short-term
negative effects on QoL and pain when making patient
treatment decisions and further support the use of sASCT.
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